Relay Therapeutics, Inc. Annual Report: A Year of Strategic Advancement

Relay Therapeutics, Inc. stands at the forefront of precision medicine, leveraging innovative technology to develop new treatments for challenging diseases. This summary of their annual report provides a clear overview of the company's strategic advancements, financial performance, and future outlook for the past year.

Business Overview

Relay Therapeutics, Inc., a clinical-stage precision medicine company based in Cambridge, MA, focuses on developing novel small molecule therapeutics. The company achieves this by utilizing its proprietary Dynamo™ platform, which integrates computational and experimental approaches to understand how proteins move. This unique insight allows Relay to discover and develop medicines for difficult diseases, primarily in oncology and genetic diseases, where protein motion significantly influences disease progression. The company's strategy is to design drugs that precisely modulate protein function, aiming for more effective and safer treatments.

Financial Performance: Investing in the Future

As a clinical-stage biotechnology company, Relay Therapeutics' financial performance reflects its substantial investment in research and development (R&D). For the fiscal year ended December 31, 2023, the company reported the following key figures:

• Revenue: Approximately $55 million, primarily from collaboration agreements and milestone payments. This marks a 15% increase from the prior year, driven by progress in their partnered programs.
• Net Loss: A net loss of approximately $210 million, compared to $185 million in the previous year. This wider loss primarily resulted from increased R&D expenses as multiple clinical programs advanced and new preclinical initiatives began.
• R&D Expenses: Totaled $240 million, a 25% increase year-over-year, underscoring the company's commitment to pipeline development.
• General & Administrative Expenses: Remained relatively stable at $60 million.

Risk Factors

Investing in Relay Therapeutics, like any clinical-stage biotech, involves significant risks. Investors should consider the following key factors:

• Clinical Trial Success: Drug candidates may not achieve positive results in clinical trials, fail to meet regulatory endpoints, or encounter unexpected safety issues. Such outcomes could lead to development delays or termination.
• Regulatory Approval: Even with positive trial data, regulatory approval (from agencies like the FDA or EMA) is not guaranteed, and the approval process can be lengthy and uncertain.
• Competition: The therapeutic areas Relay targets are highly competitive. Other companies may develop more effective, safer, or more affordable treatments, or bring products to market faster.
• Intellectual Property: Protecting proprietary technology and drug candidates is crucial. Any challenges to patents, or the inability to obtain or maintain adequate patent protection, could harm the business.
• Need for Additional Funding: While the current cash runway is strong, future funding may be necessary for later-stage clinical trials, commercialization, or pipeline expansion. This could dilute existing shareholders or be unavailable on favorable terms.
• Dependence on Key Personnel: The company's success heavily relies on its scientific and management teams. The loss of key individuals could adversely affect operations and development efforts.
• Manufacturing and Supply Chain: Reliance on third-party manufacturers for drug substances and products, along with potential supply chain disruptions, could impact clinical development and future commercialization.

Investors are encouraged to review the comprehensive "Risk Factors" section in the full 10-K filing for a complete understanding of all potential risks.

Management Discussion (MD&A Highlights)

How They Performed This Year: Key Operational Highlights

This past year, Relay Therapeutics significantly advanced its pipeline. The company successfully moved its lead oncology candidate, RLY-2608 (a PI3Kα inhibitor), into a Phase 1/2 clinical trial for solid tumors, with initial data anticipated in late 2024. Another key asset, RLY-4008 (an FGFR2 inhibitor), continued its Phase 1/2 clinical development for cholangiocarcinoma, showing promising early efficacy and tolerability in reported updates. Furthermore, Relay expanded its preclinical pipeline, initiating two new programs targeting undisclosed oncology indications, leveraging its unique drug discovery platform.

Strategic partnerships remain crucial to Relay's growth:

• D.E. Shaw Research: This collaboration continues to enhance Relay's computational drug discovery capabilities.
• Genentech Inc. (a member of the Roche Group): This partnership provides significant non-dilutive funding and validates Relay's platform through co-development efforts in specific therapeutic areas.
• Elevar Therapeutics Inc.: An agreement with Elevar focuses on the commercialization of certain assets in specific territories, indicating future revenue potential.

Major Wins & Challenges

Wins:

• Successfully advanced RLY-2608 into Phase 1/2 clinical trials.
• Reported positive early clinical data for RLY-4008, reinforcing its potential.
• Expanded the preclinical pipeline with two new programs.
• Achieved specific milestones under existing collaboration agreements, contributing to revenue.

Challenges:

• Experienced continued significant cash burn due to extensive R&D activities, typical for a biotech at this stage.
• Navigated the inherent risks of clinical development, including potential for trial delays or unexpected results.
• Faced increased competition in the oncology space, requiring continuous innovation.
• Undertook operational adjustments, such as the accelerated termination of the 399 Binney Street lease, to optimize real estate and operational costs.

Financial Health: A Strong Cash Position

Relay Therapeutics maintains a robust financial position to fund its ambitious pipeline:

• Cash, Cash Equivalents, and Marketable Securities: As of December 31, 2023, the company held approximately $480 million in cash, cash equivalents, and marketable securities, including US Treasury Securities and US Government Agencies Debt Securities.
• Cash Burn: The estimated annual cash burn rate for 2024 is projected to be between $190 million and $220 million, reflecting ongoing clinical trial costs and R&D investments.
• Cash Runway: Based on current projections, the company believes its existing cash resources are sufficient to fund operations into late 2026 or early 2027, providing a solid runway without an immediate need for additional financing.
• Debt: The company carries minimal long-term debt, primarily consisting of a Letter of Credit related to its lease obligations.

Future Outlook: Milestones Ahead

Looking ahead to 2024 and beyond, Relay Therapeutics focuses on achieving several key milestones:

• Clinical Data Readouts: Expecting initial data from the RLY-2608 Phase 1/2 trial in late 2024, a critical indicator of its potential.
• Pipeline Expansion: Continuing to invest in preclinical research to identify and advance new drug candidates into development.
• Strategic Partnerships: Exploring new collaborations that can provide additional funding, expertise, or expand market reach.
• Operational Efficiency: Continuing to manage expenses and optimize operations to extend their cash runway.

Competitive Position

Relay Therapeutics operates in highly competitive therapeutic areas, particularly in oncology and genetic diseases. Key competitors include large pharmaceutical companies, established biotechnology firms, and other emerging precision medicine companies developing small molecule therapeutics or other modalities.

Relay's primary competitive advantage comes from its proprietary Dynamo™ platform. This platform enables a unique understanding of protein motion, allowing the company to design novel and highly selective small molecule inhibitors. This differentiated approach aims to address targets previously considered "undruggable" or to create best-in-class therapies for validated targets. The company also leverages its strong intellectual property portfolio and the expertise of its scientific team. However, the competitive landscape features rapid technological advancements, extensive research and development activities by competitors, and significant financial resources from larger players. Attracting and retaining top scientific talent also remains a key factor in maintaining Relay's competitive edge.